T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors
T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) ...
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...
Medscape10d
Promise for CAR T-Cell Therapies in Solid Tumors?
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
labiotech2d
T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
Mena FN8d
T-Cell Receptor Therapy Market Poised For Remarkable Growth By 2032 Delveinsight
Unlike CAR-T cell therapy, which recognizes surface antigens, TCR therapy is engineered to identify intracellular antigens presented by major histocompatibility complex (MHC) molecules ...
Pharmabiz15h
Medigene’s JOVI technology receives US patent
Medigene AG, an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the company has been issued a ...
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies ...
Business Insider8d
T-knife Therapeutics to Participate in Two Investor Conferences in March
Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced that members of the company’s management team will ...